General Information
Intarcia ITCA 650-CLP-203
A Phase 3b, Randomized, Active Comparator, Open-label, Multicenter Study to Compare the Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and to Glimepiride as Add-on Therapy to Metformin in Patients with Type 2 Diabetes. Code number: ITCA 650-CLP-203.
| Protocol | ITCA 650-CLP-203 |
|---|---|
| Identifier | Site Number: 1254 |
| UID | 7c800acf-17b2-43d4-a144-2567b212a2bd |
| Status | Done - Archived |
| Phase | 3b |
| Category | Diabetes Type 2 / Adult |
| Launch Year | 0 |
| NCT Number | - |
| Created | 2017-03-14 11:59 |
| Last Updated | 2017-03-14 11:59 |
Description
No description provided.
Comment
PCRS
Target Dates
| Name | Date | Required |
|---|---|---|
| Enrollment Closed | No | |
| Enrollment Open | 2017-05-25 | No |
| First Patient First Visit | No | |
| Site Initiation Mtg. | 2017-05-24 | No |
| PI Meeting Start | No | |
| PI Meeting End | No | |
| PI Meeting Arrival | No | |
| PI Meeting Departure | No | |
| Closeout Date | 2018-03-14 | No |
| Final PatientVisit | No | |
| PreStudy Selection Visit | No | |
| Target Date 12 | No | |
| Target Date 13 | No | |
| Target Date 14 | No |
Leadership
| Role | Staff | Login | Required |
|---|---|---|---|
| Principal | Unger, Jeffrey | JUnger | No |
| Recruiter | Miss, Salomon | SMiss | No |
| Coordinator | Sandoval, Larry | LSandoval | No |
| Regulatory | Perez, Myrna | MPerez | No |
Custom Fields
No custom fields.
Sponsor & Organization
| Sponsor | Intarcia Therapeutics, Inc. |
|---|---|
| Division | Intarcia Therapeutics, Inc. |
| Team | Intarcia Therapeutics, Inc. |
| Managing Site | Catalina Research Institute, LLC |
| Organization |
Contacts
| IRB Ref | |
|---|---|
| CRO | IQVIA RDS Inc. |
| CRO Ref | |
| Correspondence | 0 |
Opportunity
| Probability | 0 |
|---|---|
| Comment | |
| Status Color | Gainsboro |
| Currency | - |
